90. 網膜色素変性症
[臨床試験数:103,薬物数:158(DrugBank:42),標的遺伝子数:52,標的パスウェイ数:107

Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-019079-32-PT
(EUCTR)
19/05/201005/04/2010A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemA Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration).Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9715X
INN or Proposed INN: Brimonidine Tartrate
Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9742X
INN or Proposed INN: Brimonidine Tartrate
Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9741X
INN or Proposed INN: Brimonidine Tartrate
Allergan LimitedNULLNot RecruitingFemale: yes
Male: yes
290Portugal;Czech Republic;Germany;Italy;United Kingdom
2EUCTR2010-019079-32-DE
(EUCTR)
12/05/201013/04/2010A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemA Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration).Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9715X
INN or Proposed INN: Brimonidine Tartrate
Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9742X
INN or Proposed INN: Brimonidine Tartrate
Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9741X
INN or Proposed INN: Brimonidine Tartrate
Allergan LimitedNULLNot RecruitingFemale: yes
Male: yes
290Portugal;Czech Republic;Germany;Italy;United Kingdom